A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114

NCT ID: NCT05200273

Last Updated: 2022-01-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-03-15
• Study Completion Date: 2023-12-30

Brief Summary

A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK114.

Detailed Description

This is a first-in-human (FIH), Phase 1a, multicenter, open-label, single-arm dose-escalation study of AK114 to evaluate the safety, tolerability, PK, pharmacodynamics, antitumor activity and immunogenicity in adult subjects with advanced or metastatic solid tumors. The study is comprised of dose escalation phase. Approximately 30 subjects will be treated in this study.

Conditions

Advanced or Metastatic Solid Tumors; Malignancy; Metastasis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intervention/treatment

Experimental

Group Type: EXPERIMENTAL

AK114

Intervention Type: DRUG

AK114 administered by subcutaneous injection

Interventions

AK114

AK114 administered by subcutaneous injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Written and signed informed consent

2. Age ≥ 18

3. Subjects must have histologically or cytologically confirmed advanced or metastatic solid tumor

4. Subject must have at least one measurable lesion according to RECIST v1.1

5. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1

6. At the time of Day 1 of the study, subjects with central nervous system (CNS) metastases must have been treated

7. Available archived tumor tissue sample (block or a minimum of 10 unstained slides of formalin-fixed paraffin-embedded tissues) to allow for correlative biomarker studies

8. Subjects may opt to provide two fresh biopsy samples (pretreatment and on treatment), where clinically appropriate

9. Adequate organ function

10. Use acceptable method of contraception from screening, and must agree to continue for 120 days after the final dose of investigational product

Exclusion Criteria

1. History of severe hypersensitivity reactions to other monoclonal antibodies

2. History or concurrent gastrointestinal perforation, surgery and wound healing complications, hemorrhage events

3. Patients with clinically significant cardiovascular disease

4. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of investigational product administration

5. Active or prior documented autoimmune disease within the past 2 years

6. History of primary immunodeficiency

7. History of organ transplant or hematopoietic stem cell that requires use of immunosuppressive medications

8. Known allergy or reaction to any component of the investigational product formulation.

9. History of interstitial lung disease or noninfectious pneumonitis except for those induced by radiation therapies.

10. Prior treatment with canakinumab.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Akeso

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alex HL Wong, MMedSc

Role: STUDY_DIRECTOR

Akeso

Locations

Ashford Cancer Centre

Kurralta Park, South Australia, Australia

Countries

Australia

Central Contacts

Alex HL Wong, MMedSc

Role: CONTACT

global.trials@akesobio.com

+86(0760)89873999

Other Identifiers

AK114-102

Identifier Type: -

Identifier Source: org_study_id